ClinicalTrials.gg
TerminatedNCT03746431Updated Jan 7, 2026

A Phase 1 Study of [225Ac]-FPI-1434 Injection

A Phase 1 interventional study of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection multi-dose in Advanced Solid Tumours, Endometrial Cancer and Cervical Cancer, sponsored by Fusion Pharmaceuticals Inc.. Terminated at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Fusion Pharmaceuticals Inc. (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Why this study was terminated
A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Endometrial Neoplasms by AstraZeneca — 9 open to participants now, 13 under way, 4 of them phase 3. Endometrial Neoplasms · AstraZeneca.

Enrollment
10th of 12
78 · median 457
Started
2019
the only one that year
Phase 1
3 of 17
none open now
Registered
3rd of 17
by date

Among the 17 studies in Endometrial Neoplasms by AstraZeneca, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 1, and was the 3rd registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

9 of the 17 studies in Endometrial Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Endometrial Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent).

Read the detailed description

This study consists of a Phase 1 portion and a Phase 2 portion.

Phase 1 includes the following cohorts: Single dose-ascending cohorts and Multi- dose ascending cohorts of [225Ac]-FPI-1434 and Multi- dose ascending cohorts evaluating administration of FPI-1175 (cold antibody), followed by, [225Ac]-FPI-1434 (cold + hot), with cycles repeating every 42 days. And Cold Antibody Sub-study evaluating administration of ascending doses of FPI-1175 followed by [111In]-FPI-1547.

The Phase 2 will evaluate [111In]-FPI-1547 and [225Ac]-FPI-1434 with or without FPI-1175 in tumour-specific cohorts. The decision to utilize FPI-1175 in the Phase 2 portion of the study will be determined based on Phase 1 data, including safety, tolerability, pharmacokinetic and dosimetry results.

03

Conditions studied

  • Advanced Solid Tumours
  • Endometrial Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Triple Negative Breast Cancer (TNBC)
  • HER2-negative Breast Cancer
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Adrenocortical Carcinoma
  • Uveal Melanoma

Keywords

  • 225-Ac Labelled Humanized Monoclonal Antibody Against IGF-1R
  • [225Ac]-FPI-1434
  • IGF-IR Targeted Alpha Therapeutic
  • IGF-IR Radioligand Therapy
  • Radiopharmaceuticals
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. documented, definitively diagnosed, advanced solid tumour that is to all standard treatment, for which no standard treatment is available, or it is , or the patient refuses standard therapy.
  2. Measurable or evaluable disease in accordance with 1.1.
  3. (ECOG) Performance status of 0 or 1.
  4. of greater than 3 months as judged by the treating physician.
  5. Available tumour tissue (either archival or fresh ) for IGF-1R immunohistochemistry. Submission of the tissue is not required prior to enrollment.
  6. Adequate heart, kidney, and liver function
  7. Adequate bone marrow reserves
  8. Ability to understand and the willingness to sign a written document.

    Phase 2 Specific

  9. Histologically and/or cytologically documented diagnosis of locally advanced, inoperable, , or recurrent solid tumour types: endometrial, cervical, ovarian, TNBC, HER 2-negative breast, HNSCC, ACC, or uveal melanoma.
  10. Have per RECIST 1.1 Failure to respond to standard systemic therapy, or for whom standard or curative systemic therapy does not exist or is not tolerable.

    Imaging Eligibility

  11. Prior to the initial [225Ac]-FPI-1434 cycle: Sufficient target expression in at least 1 lesion following [111In]-FPI-1547 and SPECT imaging.

Exclusion criteria

Exclusion Criteria:

  1. Systemic therapeutic radiopharmaceutical within 6 months prior to enrollment into this study.
  2. to or inability to perform the required imaging procedures in this study (e.g., inability to lay flat during scan time)
  3. Uncontrolled , including but not limited to the need for treatment with , surgery or radiation therapy.
  4. Anticancer therapy (including agents) or external beam radiation therapy within 14 days of the dosing of [111In]-FPI-1547
  5. Has known additional that is progressing or has required active treatment within the past 3 years. Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast cancer, cervical cancer, prostate) that have undergone potentially curative therapy are not excluded.
  6. Residual ≥ Grade 2 side effects of prior therapy, with the exception of residual grade 2 alopecia.
  7. Prior organ transplantation, including stem cell transplantation.
  8. Any prior treatment with nitrosoureas or actinomycin-D.
  9. levels of protein in the urine
  10. Known or suspected allergies or contraindications to the Investigational Products or any component of the investigational drug formulation.
  11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements.
  12. Received > 20 Gy prior radiation to large areas of the bone marrow
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    [225Ac]-FPI-1434 Single-Dose Escalation

    Drug: [111In]-FPI-1547 Injection · Drug: [225Ac]-FPI-1434 Injection single-dose

  • Experimental
    [225Ac]-FPI-1434 Multi-Dose Escalation

    \[225Ac\]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).

    Drug: [111In]-FPI-1547 Injection · Drug: [225Ac]-FPI-1434 Injection multi-dose · Biological: FPI-1175 Infusion

  • Experimental
    FPI-1175 Cold Antibody

    Drug: [111In]-FPI-1547 Injection · Drug: [225Ac]-FPI-1434 Injection multi-dose · Biological: FPI-1175 Infusion

  • Experimental
    [225Ac]-FPI-1434 Multi-Dose

    Phase 2 Tumour Cohort - Head \& Neck Squamous Cell Carcinoma (HNSCC), Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative, Adrenocortical Carcinoma (ACC), Uveal Melanoma, \[225Ac\]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).

    Drug: [111In]-FPI-1547 Injection · Drug: [225Ac]-FPI-1434 Injection multi-dose · Biological: FPI-1175 Infusion

Interventions

  • \[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.

  • \[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.

  • BiologicalFPI-1175 Infusion

    FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.

  • \[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Incidence of adverse events (AEs).

    Phase 1

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  2. Single-Dose Escalation: Incidence of dose limiting toxicities (DLTs).

    Phase 1

    Time frame: 8 weeks.

  3. Multi-Dose Escalation: Incidence of DLTs.

    Phase 1

    Time frame: 6 weeks.

  4. Dose Escalation: Incidence of clinically significant clinical laboratory abnormalities.

    Phase 1

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  5. Dose Escalation: Changes in electrocardiogram (ECG) parameters (PR, QRS, QT, and QTc intervals).

    Phase 1

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  6. Cold Antibody Sub-Study: Changes in uptake of [111In]-FPI-1547 Injection following FPI-1175 Infusion in selected regions of interest on SPECT/CT images.

    Phase 1

    Time frame: Within two weeks of the first [111In]-FPI-1547 Injection.

  7. Cold Antibody Sub-Study: Changes in radiation dose estimates for selected tissues, organs and whole body both for [111In]-FPI-1547 and [225Ac]-FPI-1434 Injection at various dose levels following FPI-1175 Infusion.

    Phase 1

    Time frame: Within two weeks of the first [111In]-FPI-1547 Injection.

  8. Evaluate anti-tumour activity of [225Ac]-FPI-1434 regimen

    Phase 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 injection.

  9. Objective response rate (ORR) RECIST v1.1.

    Phase 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

Secondary outcomes

  1. Dose Escalation and Cold Antibody Sub-Study: Tumour uptake of [111In]-FPI-1547 in selected regions of interest on SPECT/CT images.

    Phase 1 and 2

    Time frame: Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection.

  2. Dose Escalation: Radiation doses for selected organs and whole body both for [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.

    Phase 1 and 2

    Time frame: Within one week of the [111In]-FPI-1547 Injection.

  3. Dose Escalation and Cold-Antibody Sub-Study: Changes in radiation absorbed doses for tumour lesions for [225Ac]-FPI-1434.

    Phase 1 and 2

    Time frame: Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection.

  4. Dose Escalation and Cold-Antibody Sub-Study: Clearance for radioactivity and for the targeting antibody.

    Phase 1 and 2

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  5. Dose Escalation and Cold-Antibody Sub-Study: Area under the curve (AUC) for radioactivity and for the targeting antibody.

    Phase 1 and 2

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  6. Dose Escalation and Cold-Antibody Sub-Study: Cmax for radioactivity and for the targeting antibody.

    Phase 1 and 2

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  7. Dose Escalation and Cold-Antibody Sub-Study: Half-life for radioactivity and for the targeting antibody.

    Phase 1 and 2

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  8. Dose Escalation and Cold-Antibody Sub-Study: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Prostate Cancer Working Group 3 (PCWG3) guidelines.

    Phase 1

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  9. Dose Escalation: Changes in the corrected QT (QTc) interval in milliseconds after [225Ac]-FPI-1434 treatment, compared to baseline.

    Phase 1 and 2

    Time frame: Approximately 24 hours from the time of [225Ac]-FPI-1434 Injection administration.

  10. Dose Escalation and Cold-Antibody Sub-Study: Changes in human growth hormone (hGh) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.

    Phase 1 and 2

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  11. Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor 1 (IGF-1) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.

    Phase 1 and 2

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  12. Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor binding protein 3 (IGFBP-3) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.

    Phase 1 and 2

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  13. Cold Antibody Sub-Study: Incidence of AEs.

    Phase 1 and 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  14. Cold Antibody Sub-Study: Incidence of clinically significant clinical laboratory abnormalities.

    Phase 1 and 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  15. Cold Antibody Sub-Study: Changes in ECG parameters (PR, QRS, QT, and QTc intervals).

    Phase 1 and 2

    Time frame: 4 weeks post final [225Ac]-FPI-1434 Injection.

  16. Dose Escalation and Cold-Antibody Sub-Study: Time to response (TTR).

    Phase 1 and 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  17. Dose Escalation and Cold-Antibody Sub-Study: Duration of response (DoR).

    Phase 1 and 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  18. Dose Escalation and Cold-Antibody Sub-Study: Progression free survival (PFS).

    Phase 1 and 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  19. Dose Escalation and Cold-Antibody Sub-Study: Time to Progression (TTP).

    Phase 1 and 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  20. Dose Escalation and Cold-Antibody Sub-Study: Disease control rate (DCR).

    Phase 1 and 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

  21. Dose Escalation and Cold-Antibody Sub-Study: Overall survival (OS).

    Phase 1 and 2

    Time frame: Approximately one year post final [225Ac]-FPI-1434 Injection.

07

Study locations

13 sites
  • City of Hope
    Duarte, California 91010, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Masonic Cancer Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14203, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • Juravinski Cancer Center - Hamilton Health
    Hamilton, Ontario L8V 5C2, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2C1, Canada
  • Centre Hospitalier De I'Universite de Montreal
    Montreal, Quebec H2X 0C1, Canada
  • Quebec University Hospital- Laval
    Québec, Quebec G1R 2J6, Canada
08

References and documents

Publications

  • Anderson PM, Subbiah V, Trucco MM. Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227. Front Med (Lausanne). 2022 Nov 15;9:1030094. doi: 10.3389/fmed.2022.1030094. eCollection 2022. PubMed 36457575 ↗
  • Martiniova L, Zielinski RJ, Lin M, DePalatis L, Ravizzini GC. The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment. Cancer J. 2022 Nov-Dec 01;28(6):446-453. doi: 10.1097/PPO.0000000000000625. PubMed 36383907 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Dec 2025, 82 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 19, 2018
StartActual
Jan 17, 2019
Primary completionActual
Dec 3, 2025
CompletionActual
Dec 3, 2025
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03746431
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Jan 17, 2019
Primary completion
Dec 3, 2025
Completion
Dec 3, 2025
Last update
Jan 7, 2026

Study contacts

Julia Kazakin, MD
study director · Fusion Pharmaceuticals Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Actinium-225

Start the discussion